Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Pleural Effusion, Malignant 2Pleural Effusion 2Mesothelioma 2Solitary Pulmonary Nodule 1Pleural Diseases 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mediastinal Neoplasms 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Disease 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Sorafenib 61Bevacizumab 42Oxaliplatin 24Doxorubicin 22Radiosurgery 20Gemcitabine 20Fluorouracil 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17Capecitabine 17lenvatinib 16Cisplatin 16atezolizumab 13Leucovorin 13Radiotherapy 11tremelimumab 10Cyclophosphamide 10Carboplatin 10Irinotecan 9Ipilimumab 9Drug Therapy 9Everolimus 8Cryosurgery 8toripalimab 7fludarabine 7Sunitinib 7Chemotherapy, Adjuvant 7Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Liver Neoplasms × Thoracoscopy × Clear all
NCT04931420 2024-07-31

Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

University of Chicago

Phase 2 Withdrawn
GastrointestinalThoracic

Gastrointestinal Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡